Versant & MPM Back Synthetic Lethality Newco With $68M
Repare Therapeutics Inc., a Boston and Toronto-based cancer biotech, focusing on synthetic lethality, has hit the ground running with a $68m series A round from seasoned venture capitalists.
You may also be interested in...
Roche is paying $125m upfront to in-license potential blockbuster lead candidate camonsertib from Repare, which calls it a best-in-class ATR inhibitor and has the chance to opt back in on US commercialization.
Deal Snapshot: The drug maker is betting $30m up front and up to $1.1bn in milestone fees for an increasingly popular approach to oncology drug development.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.